NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Ocumetics Clinical Study Results and Accommodating Intraocular Lens
TL;DR
Ocumetics Technology Corp's successful clinical trial results position the company as a leader in next-generation vision correction technology with significant market advantage.
The Ocumetics Accommodating Intraocular Lens demonstrated safe implantation and achieved corrected distance visual acuity ranging from 20/32 to 20/25 in all Group 1 patients.
This advanced lens technology restores clear vision to cataract patients, significantly improving quality of life and reducing dependency on corrective eyewear.
Ocumetics' revolutionary intraocular lens allows natural eye muscles to shift focus between distances, potentially eliminating the need for glasses entirely.
Found this article helpful?
Share it with your network and spread the knowledge!
Ocumetics announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study, showing Corrected Distance Visual Acuity ranging from 20/32 to 20/25 with steady improvement in vision.
The Ocumetics Lens is an accommodating intraocular lens that fits within the natural lens compartment of the eye and is designed to allow the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses.
All Group 1 patients achieved Corrected Distance Visual Acuity ranging from 20/32 to 20/25 at their one-month postoperative exams, with every patient showing steady improvement in visual acuity.
These results have met and in some cases exceeded internal expectations, demonstrating safe implantation and strong optical performance while reinforcing the transformative potential of the technology for patients with significantly impaired vision due to cataracts.
Group 1 surgeries were completed in August 2025 (Day 1) and additional Group 1 surgeries were completed in September 2025 (Day 2), with all patients now having completed their one-month postoperative exams.
The primary objectives were to confirm safety, evaluate surgical technique, and assess distance vision restoration, all of which have been demonstrated through the results to date.
Planning for Group 2 surgeries is now underway following the successful completion of Group 1, with updates expected in the coming weeks as the company advances to Group 2 and 3 surgeries.
Dean Burns, President and CEO, stated they are 'thrilled by the visual outcomes' and Dr. Doyle Stulting, Chief Medical Officer, noted that achieving 20/32 or better vision this soon after surgery is remarkable, highlighting the excellent optical quality and stability of the lens.
Ocumetics is a Canadian research and product development company dedicated to developing advanced vision correction solutions that enhance quality of life for patients through innovative ophthalmic technologies, aiming to transform the field of ophthalmology.
For further information, contact Dave Burwell, Director of Investor Relations, at dave.burwell@ocumetics.com or (403) 410-7907.
Curated from NewMediaWire
